FDA Imposes Partial Hold on Gilead's Magrolimab Trials for AML
TL;DR
The FDA has placed a partial clinical hold on Gilead's magrolimab, a CD47 candidate for acute myeloid leukemia (AML). Gilead has halted the screening and enrollment of new patients in US trials studying the drug in AML, but patients already enrolled can continue treatment. The hold affects two Phase III studies, ENHANCE-2 and ENHANCE-3, as well as Gilead's expanded access program.
- FDA puts partial hold on Gilead's CD47 hopeful in AML Endpoints News
- US FDA puts Gilead Sciences blood cancer drug studies on hold Reuters
- Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet FierceBiotech
- Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML Business Wire
- FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials OncLive
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News